Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents

Kuwatani Masaki; Nakamura Toru; Hayashi Tsuyoshi; Kimura Yasutoshi; Ono Michihiro; Motoya Masayo; Imai Koji; Yamakita Keisuke; Goto Takuma; Takahashi Kuniyuki; Maguchi Hiroyuki; Hirano Satoshi

Title	en Clinical Outcomes of Biliary Drainage during a Neoadjuvant Therapy for Pancreatic Cancer: Metal versus Plastic Stents
Creator	en Kuwatani, Masaki NRID 1000050431375 en Nakamura, Toru NRID 1000070645796 en Hayashi, Tsuyoshi en Kimura, Yasutoshi NRID 1000080311893 en Ono, Michihiro NRID 1000080634675 en Motoya, Masayo NRID 1000060468080 en Imai, Koji en Yamakita, Keisuke en Goto, Takuma NRID 1000050646007 en Takahashi, Kuniyuki en Maguchi, Hiroyuki en Hirano, Satoshi NRID 1000050322813
Accessrights	metadata only access
Rights	http://creativecommons.org/licenses/by-nc/4.0/ en Creative Commons Attribution-NonCommercial 4.0 International
Subject	Other en Pancreatic neoplasms Other en Chemotherapy Other en Chemoradiotherapy Other en Jaundice Other en Stent NDC 490
Description	Abstract en Neoadjuvant chemotherapy/neoadjuvant chemoradiotherapy (NAC/NACRT) can be performed in patients with pancreatic cancer to improve survival. We aimed to clarify the clinical outcomes of biliary drainage with a metal stent (MS) or a plastic stent (PS) during NAC/NACRT. Between October 2013 and April 2016, 96 patients with pancreatic cancer were registered for NAC/NACRT. Of these, 29 patients who underwent biliary drainage with MS or PS before NAC/NACRT and a subsequent pancreatoduodenectomy were retrospectively analyzed with regard to patient characteristics, preoperative recurrent biliary obstruction rate, NAC/NACRT delay or discontinuation rate, and operative characteristics. The median age of the patients was 67 years. NAC and NACRT were performed in 14 and 15 patients, respectively, and MS and PS were used in 17 and 12 patients, respectively. Recurrent biliary obstruction occurred in 6% and 83% of the patients in the MS and PS groups, respectively (p<0.001). NAC/NACRT delay was observed in 35% and 50% of the patients in the MS and PS groups, respectively (p=0.680). NAC/NACRT discontinuation was observed in 12% and 17% of the patients in the MS and PS groups, respectively (p=1.000). The operative time in the MS group tended to be longer than that in the PS group (625 minutes vs 497 minutes, p=0.051), and the operative blood loss volumes and postoperative adverse event rates were not different between the two groups. MS was better than PS from the viewpoint of preventing recurrent biliary obstruction, although MS was similar to PS with regards to perioperative outcomes.
Publisher	en Editorial Office of Gut and Liver
Date	Issued2020-03
Language	eng
Resource Type	journal article
Version Type	NA
Identifier	HDL http://hdl.handle.net/2115/77822
Relation	isIdenticalTo DOI https://doi.org/10.5009/gnl18573
Journal	PISSN 1976-2283 en Gut and Liver Volume Number14 Issue Number2 Page Start269 Page End273
Oaidate	2025-01-25